Table 1 Clinical characteristics of rheumatoid arthritis patients recruited to the study
Exploratory cohort | Validation cohort | |
|---|---|---|
(n = 10) | (n = 85) | |
Sex (male/female) | 1/9 | 11/74 |
Age, mean (range) | 54.6 (38-74) | 53.6 (24-72) |
Disease duration (y), mean (range) | 10.1 (2-23) | 10.4 (1-36) |
Smoking, number (%) | 4 (40%) | 23 (27.1%) |
TJC, mean | 13.7 ± 5.8 | 15.7 ± 4.6 |
SJC, mean | 16.9 ± 6.5 | 11.5 ± 3.7 |
DAS28, mean | 5.9 ± 0.7 | 5.7 ± 0.6 |
SDAI | 39.7 ± 14.9 | 36.3 ± 10.9 |
HAQ | 2.14 ± 0.5 | 2.1 ± 0.3 |
ESR (mm), mean | 55 ± 18.62 | 55.9 ± 16.6 |
CRP (mg/dL), mean | 3.6 ± 1.12 | 3.8 ± 2.1 |
Positive rheumatoid factor, n (%) | 7 (70%) | 60 (70.6%) |
Positive anti-CCP antibody, n (%) | 4 (40%) | 59 (69.4%) |
Medication, n (%) | ||
Infliximab | 9 (90%) | 46 (54.1%) |
Etanercept | 1 (10%) | 24 (28.2%) |
Adalimumab | 0 | 15 (17.6%) |
Corticoids, n(%) | 4 (40%) | 55 (64.7%) |
Hydroxychloroquine, n (%) | 3 (30%) | 22 (25.9%) |
Azathioprine, n (%) | 0 (0%) | 5 (5.9%) |
Metotrexate, n (%) | 7 (70%) | 58 (68.2%) |
Sulfasalazine, n (%) | 1 (10%) | 7 (8.2%) |
Cyclosporine, n (%) | 1 (10%) | 2 (2.4%) |
Leflunomide, n (%) | 2 (20%) | 33 (38.8%) |